Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

113.13 +4.90 (+4.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
There are more marketplace opportunities than just AI which is why these stocks that are outperforming Nvidia have done so well. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Dividend Stocks Yielding Over 3% With Multi-Decade Payout Growth Streaks
Explore three high-yield dividend stocks that not only offer yields of 3% or more but also boast multiple decades of payout growth. 
Via InvestorPlace
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. 
Via Benzinga
Exposures Product Safety
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Evaluating BioNTech: Insights From 12 Financial Analysts
Via Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
From BioNTech SE
Via GlobeNewswire
Evaluating BioNTech: Insights From 15 Financial Analysts
Via Benzinga
GameStop And First Solar Were Among The 10 Biggest Large Cap Losers Last Week (June 16-June 22): Are These In Your Portfolio?
10 worst-performing large-cap stocks last week: GME, ENPH, ALB, BNTX, ALGN, FLSR, BALL, MBLY, BLD, JBL. Are they in your portfolio? 
Via Benzinga
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a... 
Via Benzinga
Exposures COVID-19
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
BioNTech partner MediLink Therapeutics faces a partial clinical hold from the FDA on the Phase 1 trial of BNT326/YL202 for advanced non-small cell lung cancer and HR+/HER2-negative breast cancer. 
Via Benzinga
Exposures Product Safety
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1. 
Via Benzinga
Exposures COVID-19 Product Safety
Critical Insights From BioNTech Analyst Ratings: What You Need To Know
Via Benzinga
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
Via AB Newswire
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
Via AB Newswire
What's Going On With Novavax Stock?
Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look at what's going on. 
Via Benzinga
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in... 
Via Talk Markets
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From Genmab A/S
Via Business Wire
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
Via AB Newswire
Exposures COVID-19
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
From BioNTech SE
Via GlobeNewswire
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From BioNTech SE
Via GlobeNewswire
Jim Cramer: Celestica Makes A 'Comeback,' Sell This Movie Theater Stock,
Jim Cramer called Celestica Inc. "terrific" after the Toronto-based company reported better-than-expected first-quarter financial results. 
Via Benzinga
Moderna Was Among The Best Performing Large-Cap Stocks Last Week (May 20-May 26, 2024): Are They In Your Portfolio?
Top-performing stocks last week were FSLR, MRNA, ELF, NVDA, IP, ADI, FLEX, LOGI, BNTX, and MNDY, boosted by positive news and analyst targets. 
Via Benzinga
Why Vaccine Stocks Rallied This Week
A bird flu outbreak could spur demand for vaccines from these key players, but is it likely? 
Via The Motley Fool
Experts Predict Rise In COVID-19 Cases: Vaccine Stocks Climb
Experts predict a small rise in COVID-19 cases as a newly dominant strain spreads. The new strain, KP.2, represents 28% of Covid infections in the U.S. and experts believe its mutations have made the... 
Via Benzinga
Exposures COVID-19
Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
From BioNTech SE
Via GlobeNewswire
3 Blue-Chip Stocks Set to Triple Soon
Blue-chip stocks are great additions to a portfolio. If you're looking for consistent returns, check out these blue-chip stocks to buy. 
Via InvestorPlace
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.